NYSE · NVTA

Invitae Corporation

Healthcare · Medical - Diagnostics & Research

$0.02

Down-$0.01 (-35.59%)

Updated Oct 6, 2026, 10:38 PM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap: 5.44M
P/E ratio: -0
Dividend yield: 0.00%
52-week range: — – —
Volume: 22.46M
Avg. volume: 12.85M

Price performance · NVTA

NVTA price history

1M range · 0 trading sessions · Daily adjusted prices

Data unavailable

The requested market data was not found.

Latest NVTA news

The latest Smart Investors Daily articles mentioning NVTA.

No results

No recent SID articles mention NVTA.

Latest NVTA news

The latest Smart Investors Daily articles mentioning NVTA.

Stock researchCompany · Overview

Company

Overview Forecast Earnings Dividend Financials

Market Activity

Options Insider Trades Short Interest Institutional Ownership Sentiment

Research & News

Analysis Competitors News SEC Filings SID Coverage

NVTA research

Overview

Company profile and research snapshot.

Company profile

Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus: —
Average target: $9.75
Implied upside: —
Analysts: —

NVTA recent ratings
Date	Firm	Rating	Target
Nov 13, 2023	Piper Sandler	Underweight	—
Oct 23, 2023	Goldman Sachs	Sell	—
Oct 20, 2023	Goldman Sachs	Sell	—
Aug 15, 2023	Piper Sandler	Underweight	—
Jul 24, 2023	Goldman Sachs	Sell	—

Open full forecast

News briefing

No generated briefing is available yet.

The Motley Fool · Jan 29, 2024

Is Invitae Stock a Buy Now?

Invitae shares have lost more than 80% over the past year and a half.

Zacks Investment Research · Dec 22, 2023

Despite Fast-paced Momentum, Invitae (NVTA) Is Still a Bargain Stock

Invitae (NVTA) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Investment Research · Dec 13, 2023